Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Knowing what to avoid in cryptocurrency investments can save you from costly errors. Stay informed to protect your assets.
16,150 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Curious if you can win the lottery of Social Security—that $5,251-a-month top payout in 2026? It hinges on work credi...
Former President Donald Trump pledges to release government records on aliens and UAPs, sparking a debate about trans...
When a public fundraiser surfaces after a family tragedy, questions follow. This article breaks down the ethics, the ...
In volatile markets, a company that sells essential medical devices can offer stability and income. This guide explai...
AI data centers are expanding fast, and one networking stock stands out as a compelling buy near $150. This guide bre...
Palantir has slipped significantly from its all-time high, prompting questions about a buy-the-dip opportunity. This ...
A fresh take on Steve Jobs’ ‘bozos’ mindset and three practical management tips that helped Apple win with speed and ...
When a leading floor-care company hits a rough patch, headlines follow. This look explains why Tennant stock plummeti...
NRG Energy surges to the lead in 2025, driven by Larry Coben’s leadership and a strategy to pair robust gas-fired gen...
Greycroft increased its Sportradar stake in a year where the stock fell sharply, illustrating how big investors respo...
Income-focused investors are tuning in to Energy Transfer for a high-yield dividend and steady growth. This guide exp...